D
Davis Y. Torrejon
Researcher at University of California, Los Angeles
Publications - 26
Citations - 5850
Davis Y. Torrejon is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Melanoma & Blockade. The author has an hindex of 13, co-authored 25 publications receiving 4110 citations. Previous affiliations of Davis Y. Torrejon include Hebron University.
Papers
More filters
Journal ArticleDOI
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky,Angel Garcia-Diaz,Daniel Sanghoon Shin,Helena Escuin-Ordinas,Willy Hugo,Siwen Hu-Lieskovan,Davis Y. Torrejon,Gabriel Abril-Rodriguez,Salemiz Sandoval,Lucas Barthly,Justin Saco,Blanca Homet Moreno,Riccardo Mezzadra,Bartosz Chmielowski,Kathleen Ruchalski,I. Peter Shintaku,Phillip J. Sanchez,Cristina Puig-Saus,Grace Cherry,Elizabeth Seja,Xiangju Kong,Jia Pang,Beata Berent-Maoz,Begoña Comin-Anduix,Thomas G. Graeber,Paul C. Tumeh,Ton N. Schumacher,Roger S. Lo,Antoni Ribas +28 more
TL;DR: Acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation.
Journal ArticleDOI
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Angel Garcia-Diaz,Daniel Sanghoon Shin,Blanca Homet Moreno,Justin Saco,Helena Escuin-Ordinas,Gabriel Abril Rodriguez,Jesse M. Zaretsky,Lu Sun,Willy Hugo,Xiaoyan Wang,Giulia Parisi,Cristina Puig Saus,Davis Y. Torrejon,Thomas G. Graeber,Begonya Comin-Anduix,Siwen Hu-Lieskovan,Robert Damoiseaux,Roger S. Lo,Antoni Ribas +18 more
TL;DR: Analysis of biopsy specimens from patients with melanoma confirmed interferon signature enrichment and upregulation of gene targets for STAT1/STAT2/STAT3 and IRF1 in anti-PD-1-responding tumors.
Journal ArticleDOI
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin,Jesse M. Zaretsky,Helena Escuin-Ordinas,Angel Garcia-Diaz,Siwen Hu-Lieskovan,Anusha Kalbasi,Catherine S. Grasso,Willy Hugo,Salemiz Sandoval,Davis Y. Torrejon,Nicolaos Palaskas,Gabriel Abril Rodriguez,Giulia Parisi,Ariel M. Azhdam,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Beata Berent-Maoz,I. Peter Shintaku,Dung Thi Le,Drew M. Pardoll,Luis A. Diaz,Paul C. Tumeh,Thomas G. Graeber,Roger S. Lo,Begoña Comin-Anduix,Antoni Ribas +26 more
TL;DR: It is proposed that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy.
Journal ArticleDOI
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
Leticia De Mattos-Arruda,Leticia De Mattos-Arruda,Leticia De Mattos-Arruda,Regina Mayor,Charlotte K.Y. Ng,Britta Weigelt,Francisco Martínez-Ricarte,Francisco Martínez-Ricarte,Davis Y. Torrejon,Mafalda Oliveira,Alexandra Arias,C. Raventós,Jiabin Tang,Elena Guerini-Rocco,Elena Martínez-Sáez,Sergio Lois,Oscar Marín,Xavier de la Cruz,Xavier de la Cruz,Salvatore Piscuoglio,Russel Towers,Ana Vivancos,Vicente Peg,Santiago Ramón y Cajal,Santiago Ramón y Cajal,Joan Carles,Jordi Rodon,Maria Gonzalez-Cao,Josep Tabernero,Josep Tabernero,Enriqueta Felip,Enriqueta Felip,Joan Sahuquillo,Joan Sahuquillo,Michael F. Berger,Javier Cortes,Javier Cortes,Jorge S. Reis-Filho,Joan Seoane,Joan Seoane,Joan Seoane +40 more
TL;DR: It is shown that ctDNA derived from central nervous system tumours is more abundantly present in the cerebrospinal fluid (CSF) than in plasma, allowing the identification of actionable brain tumour somatic mutations and facilitating and complement the diagnosis of leptomeningeal carcinomatosis.
Journal ArticleDOI
Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer
Susana Cedres,Susana Cedres,Davis Y. Torrejon,A. Martínez,A. Martínez,Pablo Martinez,Pablo Martinez,Alba Navarro,Esther Zamora,N. Mulet-Margalef,Enriqueta Felip +10 more
TL;DR: Elevated NLR is a predictor of shorter survival in patients with advanced NSCLC and the variation of NLR during the first cycle of treatment predicts survival, and it is found that patients with undifferentiated carcinoma and patients with NLR ≥5 had a worse survival.